At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. We focus our efforts and resources on diseases where the unmet need is great, our internal capabilities strongest, and the external science we can partner with compelling. Our goal is to use the best internal and external science to transform how diseases are treated, cured, prevented and intercepted.
Our China R&D Center is one of four hubs for Janssen’s global R&D organization and comprises end-to-end capabilities spanning drug discovery, development and delivery.
?Clinical Development – Based in Beijing and Shanghai, our development work extends to 304 sites, including 111 hospitals with 73 products and compounds in development, including 21 new products or line extensions.
?Discovery Center – Our Shanghai discovery center runs research programs on small and large molecule drug discovery, target validation, and biomarker identification, evaluation and validation, as well as phase 0 clinical trials for hepatitis B, lung cancer, and hematologic malignancies.
?Lung Cancer Center – A cross-sector center of excellence that will transform one of China’s most prevalent forms of cancer into a preventable and curable disease.
?Asia Pacific Innovation Center – One of four J&J Innovation Centers established globally to extend our network and identify early stage collaboration with scientists, entrepreneurs and innovators.
We are dedicated to leading the industry in break-through innovation in China, for China and around the world.
We are Janssen. We collaborate with the world for the health of everyone in it.
